Bull&Bear | Innate Pharma Leads Bullish Surge with 94.84% Stock Rise; Bicycle Therapeutics Drops 31.33% Among Bearish Performers

Mover TrackerFriday, Dec 13, 2024 5:00 pm ET

1min read

In the realm of bullish stocks, Innate Pharma (IPHA) saw a remarkable increase of 94.84%. The surge in Innate Pharma's stock followed the company's announcement that its TELLOMAk Phase 2 trial revealed significant symptom relief and improved quality of life for patients.

Ondas Holdings (ONDS) experienced a 37.25% rise. Ondas Holdings was chosen as the primary commercial partner for the smart infrastructure economic zone along Texas State Highway 130. The company's platform aims to provide reliable and scalable remote drone operations. The city of Austin identified over 100 potential use cases for drones, further bolstering the company's position.

HomesToLife (HTLM) saw its stock rise by 29.26%, marking four consecutive days of gains, with an increase of 93.35% over this period. The company is actively working on new initiatives to expand its business into other regions of Asia.

D-Wave Quantum (QBTS) experienced a 27.62% increase in its stock price. This upward trend may be influenced by the recent release of Google’s Willow quantum computing chip, as stocks in the quantum field continue to benefit from Willow's momentum.

Inotiv (NOTV) rose by 26.06% after insiders within the company purchased $414,000 worth of stock, as reported by recent SEC filings.

On the bearish side, Bicycle Therapeutics (BCYC) fell by 31.33%, marking its second consecutive day of declines, with a two-day total decrease of 34.52%. The company's latest trial results have raised questions among investors.

Candel Therapeutics (CADL) witnessed a decrease of 31.12%. Alongside major stocks like 8x8, Candel Therapeutics fell during pre-market trading on Friday.

Editas Medicine (EDIT) experienced a drop of 23.81%, marking its fourth consecutive day of declines, with a total decrease of 35.43% over four days. The stock's fall came after Stifel and Chardan Capital downgraded the company's rating, and several other firms adjusted their target prices downward.

Jupiter Neurosciences (JUNS) saw a decline of 20.56% following its initial public offering, where it raised $11 million to fund Parkinson’s disease clinical trials and global expansion initiatives.

CSP (CSPI) fell by 17.90% amidst considerations by its largest shareholder, Neil Kreisberg, to pursue a privatization acquisition.

Disclaimer: the above is a summary showing certain market information. AInvest is not responsible for any data errors, omissions or other information that may be displayed incorrectly as the data is derived from a third party source. Communications displaying market prices, data and other information available in this post are meant for informational purposes only and are not intended as an offer or solicitation for the purchase or sale of any security. Please do your own research when investing. All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Keep in mind that while diversification may help spread risk, it does not assure a profit, or protect against loss in a down market.